Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 27 Nov 23 EFFECT Notice of effectiveness
- 20 Nov 23 POS AM Prospectus update (post-effective amendment)
- 27 Apr 23 424B2 Prospectus for primary offering
- 23 Mar 23 424B5 Prospectus supplement for primary offering
- 22 Mar 23 424B5 Prospectus supplement for primary offering
- 7 Feb 23 424B2 Prospectus for primary offering
- 17 May 22 424B2 Prospectus for primary offering
- 14 Dec 21 424B2 Prospectus for primary offering
- 8 Dec 21 EFFECT Notice of effectiveness
- 3 Dec 21 S-3/A Shelf registration (amended)
-
24 Nov 21 S-3 Shelf registration
ACER similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acer Therapeutics Inc.
Newton, Massachusetts
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 1, 2021, relating to the financial statements of Acer Therapeutics Inc. appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP |
Boston, Massachusetts November 24, 2021 |